DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
5 Low Price-to-Book Stocks to Increase Your Portfolio's Value
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
DVA vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. AMED: Which Stock Is the Better Value Option?
5 Buffett-Style Value Picks Boasting Impressive PEG Ratio
by Urmimala Biswas
While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.
Zacks.com featured highlights include: DaVita, Hibbett, First Horizon, Universal Forest and Popular
by Zacks Equity Research
Zacks.com featured highlights include: DaVita, Hibbett, First Horizon, Universal Forest and Popular
5 Stocks With Amazingly Low EV/EBITDA Ratios to Own Now
by Anindya Barman
We have screened value stocks based on EV/EBITDA ratio that offers a clearer picture of a company's valuation and earnings potential.
The Zacks Analyst Blog Highlights: Exantas, Chemed, Viad, Arbor Realty and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exantas, Chemed, Viad, Arbor Realty and DaVita
Strong ISM Services Index Eases Recession Fears: 5 Top Picks
by Nalak Das
The ISM Services index clearly reflects that the U.S. economy has sustained its momentum despite heightened trade conflict and global economic slowdown.
5 Price-to-Book Value Picks for September
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Why Is DaVita HealthCare (DVA) Down 5% Since Last Earnings Report?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
When to Buy Global Markets?
by John Blank
It is NOT crazy to study global markets now.
Draghi Says Goodbye. Should You Care?
by John Blank
The answer is yes. A monetary policy regime change matters.
5 Stocks From the Best Performing Sectors in Q2
by Zacks Equity Research
We have shortlisted solid stocks from the top-performing sectors in Q2 that should make a great addition to your portfolio.
RingCentral, Tapestry, JD.com, DaVita and Aercap highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
RingCentral, Tapestry, JD.com, DaVita and Aercap highlighted as Zacks Bull and Bear of the Day
Here's Why You Should Invest in DaVita (DVA) Stock For Now
by Zacks Equity Research
DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.
Challenges for Monetary Policy: Global Week Ahead
by John Blank
Big-name retailers take center stage. Major department store earnings continue to disappoint. However, big-box retailers may tell us a different story about retail.
Is DaVita (DVA) a Profitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.
5 Price-to-Book Value Picks to Improve Portfolio Returns
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Outlook for Outpatient and Home Healthcare Industry Looks Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.
The Zacks Analyst Blog Highlights: Alamos Gold, Chemed, Safehold, Franco-Nevada and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alamos Gold, Chemed, Safehold, Franco-Nevada and DaVita
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
5 Safe Picks Amid Yield Inversion and Geopolitical Concerns
by Nalak Das
Throughout this month, U.S. stock markets are witnessing extreme volatility. Equities are suffering as investors are flocking to safe-haven sovereign bonds.
Zacks.com featured highlights include: DaVita, Kraton, ADT, Universal Forest Products and International Game
by Zacks Equity Research
Zacks.com featured highlights include: DaVita, Kraton, ADT, Universal Forest Products and International Game
Why DaVita HealthCare (DVA) Might be Well Poised for a Surge
by Zacks Equity Research
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
A Time to Shift Gears: Zacks August Strategy
by John Blank
The latest Q2 GDP report showed us that the consumer is solid, but business fixed investment is lackluster.